Neviah Genomics

Early Detection of Drug-induced Toxicity

Health Tech & Life Sciences
Non Active, Oct 2017
Series A Yavne Founded 2012
Total raised
Last: Series A 2012-08
Stage
Series A
Founded
2012
Headcount
31
HQ
Yavne
Sector
Health Tech & Life Sciences

About

Neviah Genomics is the inventor and developer of PropheTox, a drug toxicity screening service. Based on the mathematical analysis of cell behavior following exposure to multiple toxic and non-toxic compounds, PropheTox's innovatve assay design and optimized decision support algorithms allow the detection of low-dose, chronic toxic effects. The predictive quality of the PropheTox technology is developed through an iterative process involving toxicity assays, machine learning, and prior biological knowledge. The predictor is based on non-trivial analysis of expression data from experiments exposing primary liver cells to compounds with known toxicity, and representing a wide variety of liver toxicity pathways.

Funding history · 1 round · — total

2012-08
Series A Undisclosed

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyTest Diagnostics & Screening
Technologies
Artificial IntelligenceMachine Learning
Target customers
Healthcare & Life SciencesHealthcarePatientsLaboratoriesLife SciencesPharmaceuticals
Business model
B2B

Tags

biotechnologydiagnosticslaboratoriesbioinformaticspharma-companiesbiomarkersmachine-learningdrug-discovery